FDA Approves AstraZeneca's Datroway For Pretreated Breast Cancer Patients

1. FDA approves AstraZeneca's Datroway for advanced HR-positive breast cancer. 2. Datroway reduced disease progression risk by 37% compared to chemotherapy. 3. Median progression-free survival for Datroway was 6.9 months versus 4.9 months. 4. Safety profile consistent; ILD rate at 4.2%, mostly low grade. 5. AstraZeneca's stock rose 2.43% following the approval news.